Is Methylone legal in Poland?

Also known as: bk-MDMA

Legal status

Controlled. Poland names this substance in its own national list. «METYLON» is entry lp. 62 in group II-P of Załącznik nr 1, the psychotropic annex, with the alternative names 3,4-metylenodioksymetkatynon and bk-MDMA. Article 33(1) of the 2005 Act allows group II-P to be used for medical, industrial or research purposes. MDMA itself is a tier stricter, at lp. 65 of group I-P, so the ketone and the parent are not in the same group.

Consequences if caught

Capital exposure: none. Poland has no death penalty, and the heaviest band the 2005 Act reaches for any conduct with this substance is a term of years. Possession is an offence under article 62(1) of the 2005 Act and the band there is up to three years. Where the quantity is considerable, article 62(2) sets a band of one year to ten years. In a case of lesser gravity article 62(3) provides instead for a fine, a restriction of liberty or up to one year. Article 62a lets proceedings be discontinued, even before the decision to open an investigation, where the quantity is insignificant and intended for the holder's own use and a penalty would be inexpedient. That is a power of the prosecutor and not an entitlement of the holder, so it is not decriminalisation. The 2025 amending regulation added dipentylone at lp. 80 of the same group, which is the N,N-dimethyl pentyl homologue of this entry, so the family continues to be extended one compound at a time. Supply offences sit apart from possession. Article 56 punishes putting such a substance on the market with a fine and six months to eight years, and article 56(3) raises that to a fine and two years to twelve years where the quantity is considerable. Article 59(1) punishes supply for gain with one year to ten years. The published Poland entry dates the national naming to an amendment of 1 April 2011 in a batch of synthetic cathinones. That date is carried forward from the published Poland entry and was not re-derived in this pass.

If prescribed or medical

There is no authorised medicinal product with this substance in Poland, so no prescription route exists for it. Article 33(1) would permit a medical use of a group II-P substance, and no marketing authorisation has been granted for this one.

Documentation

No personal import route exists, because a listed substance may be brought in only under the licensing chapter of the 2005 Act and not on a traveller's own account. The certificate issued under article 75 of the Convention implementing the Schengen Agreement is the route for a prescribed controlled medicine and does not reach a substance for which no prescription can be written. Powder bought online is an import of a listed group II-P psychotropic, and the 2025 addition of dipentylone shows the family being extended by name.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Poland’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.